Lead Product(s): B-VEC
Therapeutic Area: Dermatology
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Investment January 24, 2020
Krystal Biotech intends to make the clinical material for an upcoming phase 3 trial of B-VEC at its Ancoris facility and anticipates starting the trial in Q1 2020.